Recent developments in HIV prevention — including the FDA approval of a 6‑month injectable option and updated clinical guidance — are changing the landscape of Pre-Exposure Prophylaxis (PrEP) therapy. This course reviews the latest developments, compares prevention strategies, and examines how these changes affect PrEP delivery, counseling, and monitoring. You will gain timely insights to better counsel patients, support adherence, and contribute to prevention strategies in your practice.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
David Hachey, PharmD, AAHIVP
Professor
Idaho State University

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe key new HIV PrEP therapy options recently approved or recommended, including their dosing schedules and clinical indications.
2. Identify pharmacist responsibilities when counseling patients about PrEP, including initiation, adherence, monitoring, and risk-benefit discussions.

Rachel Maynard and David Hachey have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-049-H01-P
Initial release date: 2/9/2026
Expiration date: 2/9/2027
Additional CPE details can be found here.

With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Reemal Zaheer, PharmD, CSP
Pharmacist
Johns Hopkins Medicine

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of biosimilars in the treatment of inflammatory conditions.
2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies.

Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-045-H01-P
Initial release date: 2/2/2026
Expiration date: 2/2/2027
Additional CPE details can be found here.

Join us for a special live episode of Independent Insights as we sit down with members of the National Independent Advisory Board (NIAB), at McKesson ideaShare, to explore their vision for the future of pharmacy. Hear firsthand what they’ve learned from McKesson ideaShare (MiS), what excites them most about the road ahead, and how they’re working to elevate the voice of independent pharmacy across the country.

Host
Suzanne Feeney, PharmD
Sr. Director, Pharmacy Solutions
McKesson / Health Mart

Guests
Shelby Knott, PharmD
Owner
Warren Pharmacy

Emmanuel Ayanjoke, PharmD
Owner
Altev Community Pharmacy

Ghada Abukuwaik, RPh
Owner
Curemed Pharmacy

Resources
Tune into Episode 16: Episode 16: Creating Pharmacy’s Future
To listen to APhA President Randy McDonough and Chief Pharmacist Nancy Lyons as they discuss urgent changes and a bold vision for the future of independent pharmacy on this episode of Independent Insights.

References
Listen to Episode 17: From Aisles to Action: Welcoming Legislators into Your Pharmacy.


The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Erin Raney, PharmD
Professor
Midwestern University College of Pharmacy

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy.
2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.

Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-044-H01-P
Initial release date: 1/26/2026
Expiration date: 1/26/2027
Additional CPE details can be found here.

Ranitidine — once withdrawn from the market over safety concerns — was recently re‑approved by the FDA in a reformulated version, raising important questions for pharmacists and patients alike. This course outlines the FDA’s recent approval, reviews the reformulated product's changes (including manufacturing and labeling), and examines practical considerations for dispensing, counseling, and patient safety. You will gain clarity on when ranitidine may be appropriate for use (again) and how to guide patients confidently in its safe use.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
K. Ashley Garling-Nanez, PharmD
Assistant Director of Program
UT Center of Health Communications

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize the major safety and regulatory issues that prompted ranitidine's withdrawal, and the changes made in the reformulated product approved in 2025.
2. Describe pharmacist‑relevant considerations for dispensing, patient counseling, and transition from alternative acid‑reducing therapies.

Rachel Maynard and K. Ashley Garling-Nanez have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-043-H01-P
Initial release date: 1/19/2026
Expiration date: 1/19/2027
Additional CPE details can be found here.

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Christina O'Connor, PharmD, BCPS, BCIDP
Clinical Pharmacy Manager
Mayo Clinic

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence.
2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education.

Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-038-H01-P
Initial release date: 1/12/2026
Expiration date: 1/12/2027
Additional CPE details can be found here.

Corticosteroids in the treatment of community-acquired pneumonia (CAP) remain a topic of clinical curiosity and mixed opinions. In this unique episode, two expert guests share opposing perspectives—one advocating for corticosteroid use in CAP and the other urging caution—offering pharmacists a balanced view of the current evidence and practice considerations. Tune in to explore both sides of the debate and walk away with insights to inform your role in collaborative patient care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUESTS
Sam Markle, PharmD
Critical Care Pharmacist
Sanford Health

Tristan Houle, PharmD
PGY2 Critical Care Pharmacy Resident
Sanford Health

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current evidence supporting and challenging the use of corticosteroids in the treatment of community-acquired pneumonia (CAP).
2. Identify key considerations for pharmacists when evaluating corticosteroid use as adjunctive therapy in CAP.

Rachel Maynard, Sam Markle, and Tristan Houle have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-032-H01-P
Initial release date: 1/5/2026
Expiration date: 1/5/2027
Additional CPE details can be found here.

In this episode, host Suzanne Feeney, PharmD, Senior Director, Pharmacy Solutions at McKesson Health Mart and guest Jaime Montuoro, PharmD, Director of Education & Practice Advancement at McKesson Health Mart, unpack two strategies you can deploy now: PGY1 community-based residencies and pharmacy credentialing. You’ll learn how residency trained pharmacists can elevate clinical care in workflow, fuel change and help launch billable services. Then, we get practical on credentialing—why becoming “provider ready” matters and how claiming your team’s Pharmacy Profiles credentials streamlines payer opportunities. Jaime shares real-world wins, including how Bryant Family Pharmacy partnered with a resident to implement prescriptive authority programs patients were willing to pay for. If you’re ready to move beyond the transaction and build sustainable, community anchored care, this playbook will help you start today.

Host
Suzanne Feeney, PharmD
Sr. Director, Pharmacy Solutions
McKesson / Health Mart

Guest
Jaime Montuoro, PharmD
Director, Education and Practice Advancement
McKesson / Health Mart

Resources
Tune into Episode 11: Maximizing Operations Through Proactive Workflow

Health Mart Pharmacies can access Health Mart University (HMU) for:

• Health Mart pharmacists to claim their CE credit for weekly GameChangers episodes

References
Learn more about the Health Mart Postgraduate Year One Community-based Pharmacy Residency Program here

Pharmacy Profiles is a pharmacy-friendly database that allows pharmacy teams to showcase their training and certifications in one place. If you’re a Health Mart pharmacy demonstrate your pharmacy’s readiness to receive potential patient care opportunities more quickly by having your pharmacy professionals claim their MYPROFILE. Learn more here: my.pharmacyprofiles.com. Pharmacy Profiles is a Strategic Health Alliance II, Inc., vendor.

The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.